UBC9 Antibody (C-12): sc-271057

UBC9 Antibody (C-12) is a mouse monoclonal IgG1 kappa light chain antibody that detects UBC9 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). UBC9 (C-12) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. UBC9, also known as UBE2I, plays a crucial role in the ubiquitin-like modification process, specifically in the conjugation of small ubiquitin-like modifier (SUMO) proteins to target substrates, which is essential for regulating various cellular functions. UBC9 is primarily located in the nucleus, where UBC9 participates in critical processes such as transcriptional regulation, DNA repair, and cell cycle progression. Nuclear localization of UBC9 is vital because UBC9 allows for the timely modification of nuclear proteins, thereby influencing gene expression and cellular responses to stress. UBC9′s interaction with transcription factors and mitotic regulators underscores UBC9′s importance in maintaining cellular homeostasis and facilitating proper cell division. Understanding UBC9′s role in these processes can provide insights into potential implications in diseases characterized by dysregulated protein modification, such as cancer and neurodegenerative disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

UBC9 Antibody (C-12) References:

1. Characterization of the mUBC9-binding sites required for E2A protein degradation.  |  Huggins, GS., et al. 1999. J Biol Chem. 274: 28690-6. PMID: 10497239
2. The ubiquitin-conjugation system.  |  Jentsch, S. 1992. Annu Rev Genet. 26: 179-207. PMID: 1336336
3. Meiosis and small ubiquitin-related modifier (SUMO)-conjugating enzyme, Ubc9.  |  Sakaguchi, K., et al. 2007. FEBS J. 274: 3519-3531. PMID: 17608723
4. UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts.  |  Gupta, MK., et al. 2016. Circ Res. 118: 1894-905. PMID: 27142163
5. Observation of an E2 (Ubc9)-homodimer by crystallography.  |  Alontaga, AY., et al. 2016. Data Brief. 7: 195-200. PMID: 27408909
6. Autophagy regulates UBC9 levels during viral-mediated tumorigenesis.  |  Mattoscio, D., et al. 2017. PLoS Pathog. 13: e1006262. PMID: 28253371
7. Post-Assembly Modification of Protein Cages by Ubc9-Mediated Lysine Acylation.  |  Levasseur, MD., et al. 2022. Chembiochem. 23: e202200332. PMID: 35951442
8. Protein degradation or regulation: Ub the judge.  |  Hochstrasser, M. 1996. Cell. 84: 813-5. PMID: 8601303
9. Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9.  |  Wang, ZY., et al. 1996. J Biol Chem. 271: 24811-6. PMID: 8798754
10. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9.  |  Gong, L., et al. 1997. J Biol Chem. 272: 28198-201. PMID: 9353268
11. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2.  |  Saitoh, H., et al. 1998. Curr Biol. 8: 121-4. PMID: 9427648
12. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2.  |  Okuma, T., et al. 1999. Biochem Biophys Res Commun. 254: 693-8. PMID: 9920803

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-UBC9 Antibody (C-12) has 25 citations in a variety of scientific publications.

Primary antibodies like Anti-UBC9 Antibody (C-12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

UBC9 Antibody (C-12) Specifications

Alternate Product Name: UBC9

Product Clone Name: C-12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-81

Epitope Target: UBC9

Epitope Species: human

Product Reactivity/Detection: UBC9

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine, porcine and avian

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 25 citations in various scientific publications

Available Conjugates/Forms for UBC9 Antibody (C-12): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin